Ozanimod Hydrochloride
Brand Names: Zeposia
Methodology & AI Transparency ⓘ
Ozanimod Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Ozanimod Hydrochloride (Kit and .92 mg/1 Capsule; NDC 59572-890, 59572-810) as a systemic sphingosine 1-phosphate receptor modulator formulation manufactured/labeled by Celgene Corporation when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
- 2 Real-world patient consensus: 89% patient "Worth It" rating across 12 anonymous logs for Ozanimod Hydrochloride (RxNorm RXN-59572890-2388).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $64.39 cash mean against $157.76 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Ozanimod Hydrochloride include nausea (8.5%), headache (7.1%), dizziness (5.1%).
Ask our AI Specialists anything about Ozanimod Hydrochloride
Ozanimod Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Ozanimod Hydrochloride (Kit and .92 mg/1 Capsule; NDC 59572-890, 59572-810) as a systemic sphingosine 1-phosphate receptor modulator formulation manufactured/labeled by Celgene Corporation when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Ozanimod Hydrochloride exerts selective sphingosine 1-phosphate receptor modulator pharmacodynamic activity across Kit and .92 mg/1 Capsule (systemic route, manufactured/labeled by Celgene Corporation), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 59572-890, 59572-810).
Systemic exposure to Ozanimod Hydrochloride reflects Estimated 60%–72% oral systemic absorption for Ozanimod Hydrochloride absorption kinetics and phase i/ii hepatic conjugation of ozanimod hydrochloride coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 9–20 hours terminal plasma half-life for Ozanimod Hydrochloride half-life window (peak plasma concentration (tmax) reached 1–2 hours post-dose for ozanimod hydrochloride response profile).
Dosing protocols (Kit or .92 mg/1 Capsule) balance efficacy (89.00% patient satisfaction across 12 logs) against nausea (8.5% of reports), headache (7.1% of reports), dizziness (5.1% of reports), with strict avoidance in prior anaphylaxis, angioedema, or severe hypersensitivity to ozanimod hydrochloride or ozanimod hydrochloride excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 ozanimod hydrochloride spl.
Avoid overlapping sphingosine 1-phosphate receptor modulator prescriptions alongside Ozanimod Hydrochloride to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Ozanimod Hydrochloride maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Ozanimod Hydrochloride or Ozanimod Hydrochloride excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Ozanimod Hydrochloride SPL
Logged Side-Effect Incidence (12 Reports)
Ozanimod Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ozanimod Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for: What a 1,057-Participant Study Found Clinical and radiological outcomes generally favored DRF versus IFN. Journal of comparative effectiveness research • 2024-10-15 • Phase III Randomized Trial | N = 1,057 | 96/100 | PMID 39158844 ↗ |
| Can This Approach Help? Inside the Latest Research on Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Ozanimod is an effective, durable, and well-tolerated oral therapy for AT-naive ulcerative colitis patients. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2024-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38723981 ↗ |
| New Insights on Heart and blood vessel Safety of Ozanimod in Patients With Ulcerative Colitis:: What a 796-Participant Study Found No new heart and blood vessel safety signals were identified, consistent with findings from previous ozanimod studies. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2024-05-15 • Phase III Randomized Trial | N = 796 | 87/100 | PMID 38040274 ↗ |
| Can This Approach Help? Inside the Latest Research on Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple These data suggest that plasma GFAP is a relapse-independent metric of baseline disease severity and a predictor of treatment response in participants with RMS. European journal of neurology • 2025-06-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40462564 ↗ |
Ozanimod Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.3800/unit (~$41.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $157.76 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $64.39 / mo | View logs ↓ |
Ozanimod Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ozanimod Hydrochloride RxNorm Concept ID | RXN-59572890-2388 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.3800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $157.76 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $64.39 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ozanimod Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Deterministic Ozanimod Hydrochloride reference combining NIH RxNorm (RXN-59572890-2388), Medicaid NADAC ($1.3800/unit), and anonymous cohort outcomes (89% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ozanimod Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.